	US 7,572,442 B2
	Selected antibody compositions for binding to aminophospholipids
Philip E. Thorpe, Dallas, Tex. (US); and Sophia Ran, Riverton, Ill. (US)
Assigned to Board of Regents, The University of Texas System, Austin, Tex. (US)
Filed on Jul. 15, 2003, as Appl. No. 10/621,269.
Claims priority of provisional application 60/396263, filed on Jul. 15, 2002.
Prior Publication US 2004/0170620 A1, Sep. 02, 2004
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/00 (2006.01); C07K 16/30 (2006.01)

U.S. Cl. 424—130.1 [424/141.1; 424/155.1; 530/387.1; 530/388.1; 530/388.8]

30 Claims

1. A composition comprising a first purified antibody, or antigen-binding fragment thereof, and at least a second therapeutic agent; wherein said first antibody or antigen-binding fragment thereof comprises at least two variable regions that each comprises three CDRs, wherein said two variable regions are:

(a) a heavy chain variable region that comprises variable heavy (VH) CDR1, VH CDR2 and VH CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VH CDR1 has the amino acid sequence of SEQ ID NO:10, said VH CDR2 has the amino acid sequence of SEQ ID NO:11 and said VH CDR3 has the amino acid sequence of SEQ ID NO:12; and

(b) a light chain variable region that comprises a variable light (VL) CDR1, VL CDR2 and VL CDR3 from the monoclonal antibody 3G4, produced by hybridoma ATCC PTA 4545, wherein said VL CDR1 has the amino acid sequence of SEQ ID NO:13, said VL CDR2 has the amino acid sequence of SEQ ID NO:14 and said VL CDR3 has the amino acid sequence of SEQ ID NO:15.